164 related articles for article (PubMed ID: 28787430)
1. GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS).
Mora J; Castañeda A; Perez-Jaume S; Lopez-Pousa A; Maradiegue E; Valverde C; Martin-Broto J; Garcia Del Muro X; Cruz O; Cruz J; Martinez-Trufero J; Maurel J; Vaz MA; de Alava E; de Torres C
Br J Cancer; 2017 Sep; 117(6):767-774. PubMed ID: 28787430
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma.
Lee EM; Rha SY; Lee J; Park KH; Ahn JH
Cancer Chemother Pharmacol; 2012 Mar; 69(3):635-42. PubMed ID: 21959979
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.
Fox E; Patel S; Wathen JK; Schuetze S; Chawla S; Harmon D; Reinke D; Chugh R; Benjamin RS; Helman LJ
Oncologist; 2012; 17(3):321. PubMed ID: 22363068
[TBL] [Abstract][Full Text] [Related]
5. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
[TBL] [Abstract][Full Text] [Related]
6. Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1.
Brunetto AL; Castillo LA; Petrilli AS; Macedo CD; Boldrini E; Costa C; Almeida MT; Kirst D; Rodriguez-Galindo C; Pereira WV; Watanabe FM; Pizza M; Benites E; Morais V; Gadelha A; Nakasato A; Abujamra AL; Gregianin LJ;
Pediatr Blood Cancer; 2015 Oct; 62(10):1747-53. PubMed ID: 25917418
[TBL] [Abstract][Full Text] [Related]
7. A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.
Davis EJ; Chugh R; Zhao L; Lucas DR; Biermann JS; Zalupski MM; Feng M; Wong SL; Jacobson J; Zyczynski L; Reinke D; Metko G; Baker LH; Schuetze SM
Eur J Cancer; 2015 Sep; 51(13):1794-802. PubMed ID: 26066736
[TBL] [Abstract][Full Text] [Related]
8. Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel.
Mora J; Cruz CO; Parareda A; de Torres C
J Pediatr Hematol Oncol; 2009 Oct; 31(10):723-9. PubMed ID: 19727011
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma.
Kaya AO; Büyükberber S; Ozkan M; Alkiş N; Sevinc A; Ozdemir NY; Alici S; Esbah O; Berk V; Camci C; Ulas A; Coskun U; Benekli M;
Asian Pac J Cancer Prev; 2012; 13(2):463-7. PubMed ID: 22524807
[TBL] [Abstract][Full Text] [Related]
10. High Response Rates and Promising Outcomes of Patients with Relapsed Ewing Sarcoma, Especially in Adolescents and Young Adults Treated on a Novel Hybrid Salvage Chemotherapy Regimen.
Vijayasekharan K; Ramanathan S; Chinnaswamy G; Prasad M; Gulia A; Janu A; Rekhi B; Ramadwar M; Khanna N; Laskar S; Puranadare N; Bajpai J; Puri A; Banavali S; Vora T
J Adolesc Young Adult Oncol; 2021 Apr; 10(2):185-192. PubMed ID: 32706630
[No Abstract] [Full Text] [Related]
11. Phase II trial of gemcitabine and nab-paclitaxel in patients with recurrent Ewing sarcoma: A report from the National Pediatric Cancer Foundation.
Oesterheld JE; Reed DR; Setty BA; Isakoff MS; Thompson P; Yin H; Hayashi M; Loeb DM; Smith T; Makanji R; Fridley BL; Wagner LM
Pediatr Blood Cancer; 2020 Jul; 67(7):e28370. PubMed ID: 32386107
[TBL] [Abstract][Full Text] [Related]
12. A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors.
Yoon JH; Kwon MM; Park HJ; Park SY; Lim KY; Joo J; Park BK
BMC Cancer; 2014 Aug; 14():622. PubMed ID: 25164234
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy and gemcitabine-docetaxel chemotherapy in children and adolescents with unresectable recurrent or refractory osteosarcoma.
Lee JA; Paik EK; Seo J; Kim DH; Lim JS; Yoo JY; Kim MS
Jpn J Clin Oncol; 2016 Feb; 46(2):138-43. PubMed ID: 26685322
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine and docetaxel combination chemotherapy for advanced bone and soft tissue sarcomas: protocol for an open-label, non-randomised, Phase 2 study.
Hara H; Kawamoto T; Fukase N; Kawakami Y; Takemori T; Fujiwara S; Kitayama K; Nishida K; Kuroda R; Akisue T
BMC Cancer; 2019 Jul; 19(1):725. PubMed ID: 31337342
[TBL] [Abstract][Full Text] [Related]
16. Ewing's sarcoma: only patients with 100% of necrosis after chemotherapy should be classified as having a good response.
Albergo JI; Gaston CL; Laitinen M; Darbyshire A; Jeys LM; Sumathi V; Parry M; Peake D; Carter SR; Tillman R; Abudu AT; Grimer RJ
Bone Joint J; 2016 Aug; 98-B(8):1138-44. PubMed ID: 27482030
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors and patterns of relapse in ewing sarcoma patients treated with chemotherapy and r0 resection.
Pan HY; Morani A; Wang WL; Hess KR; Paulino AC; Ludwig JA; Lin PP; Daw NC; Mahajan A
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):349-57. PubMed ID: 25772182
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone.
Palmerini E; Jones RL; Marchesi E; Paioli A; Cesari M; Longhi A; Meazza C; Coccoli L; Fagioli F; Asaftei S; Grignani G; Tamburini A; Pollack SM; Picci P; Ferrari S
BMC Cancer; 2016 Apr; 16():280. PubMed ID: 27098543
[TBL] [Abstract][Full Text] [Related]
19. Outcomes with nondose-dense chemotherapy for Ewing sarcoma: A practical approach for the developing world.
Parambil BC; Vora T; Sankaran H; Prasad M; Bakshi A; Puri A; Gulia A; Qureshi S; Laskar S; Khanna N; Shah S; Ramadwar M; Kembhavi S; Chinnaswamy G; Banavali S
Pediatr Blood Cancer; 2020 Nov; 67(11):e28604. PubMed ID: 32706522
[TBL] [Abstract][Full Text] [Related]
20. The value of high-dose chemotherapy in patients with first relapsed Ewing sarcoma.
Rasper M; Jabar S; Ranft A; Jürgens H; Amler S; Dirksen U
Pediatr Blood Cancer; 2014 Aug; 61(8):1382-6. PubMed ID: 24729428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
